Cargando…
Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
BACKGROUND: Dupilumab, targeting the interleukin-4α receptor and inhibiting the action of interleukin-4 and interleukin-13, was recently approved for treatment of moderate to severe atopic dermatitis. There is limited data on long-term effects and safety among patients with severe atopic dermatitis...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510313/ https://www.ncbi.nlm.nih.gov/pubmed/32962676 http://dx.doi.org/10.1186/s12895-020-00103-0 |